How does magnesium sulfate benefit patients with preeclampsia?

How Magnesium Sulfate Benefits Preeclampsia

Magnesium sulfate prevents eclamptic seizures in preeclampsia by approximately halving the seizure rate, with about 100 women needing treatment to prevent one seizure. 1

Primary Mechanism: Seizure Prevention

Magnesium sulfate works by blocking neuromuscular transmission and decreasing acetylcholine release at the motor nerve end-plate, thereby preventing or controlling convulsions. 2 The drug has a depressant effect on the central nervous system without adversely affecting the woman, fetus, or neonate when used appropriately. 2

Evidence Base for Seizure Prevention

• The landmark MAGPIE trial demonstrated clear superiority of magnesium sulfate over other anticonvulsants for eclampsia prevention 1
• In women with eclampsia, recurrent seizures occurred in 23.1% (216/935) of those treated with phenytoin or diazepam, compared to only 9.4% (88/932) of magnesium-treated women 3
• In women with severe preeclampsia, seizures occurred in 2.8% (22/793) of those treated with antihypertensive agents alone, compared to only 0.9% (7/815) of magnesium-treated women 3
• Effective anticonvulsant serum levels range from 2.5 to 7.5 mEq/L 2

Secondary Hemodynamic Benefits

Beyond seizure prevention, magnesium sulfate provides favorable cardiovascular effects specifically in preeclamptic patients:

Vascular Effects

• Magnesium sulfate causes sustained reduction in systemic vascular resistance and increases cardiac index in preeclamptic patients 4
• At baseline, preeclamptic patients have elevated systemic vascular resistance (2465 ± 718 F.ohm/m²) and reduced cardiac index (3.6 ± 1.0 L/min/m²) 4
• These hemodynamic improvements persist for at least 4 hours after initiation of therapy 4
• Magnesium produces peripheral vasodilation, with larger doses causing blood pressure lowering 2

Cerebral Blood Flow

• Magnesium sulfate significantly reduces the pulsatility index in the middle cerebral artery (change = -0.16 ± 0.09 vs placebo -0.02 ± 0.06, p=0.01) 5
• This suggests vasodilation of smaller-diameter intracranial vessels distal to the middle cerebral artery 5
• The drug may exert its main anticonvulsant effect by relieving cerebral ischemia 5

Uteroplacental Perfusion

• At 30-34 weeks gestation, magnesium sulfate improves blood flow in uterine, umbilical, and fetal middle cerebral arteries 6
• Resistance index in uterine arteries, umbilical arteries, and middle cerebral arteries all decrease significantly after treatment 6
• This improvement in uteroplacental blood flow may help manage fetal growth restriction associated with severe preeclampsia 6

Clinical Indications and Dosing

Who Should Receive Magnesium Sulfate

The ISSHP recommends all preeclamptic women in low- and middle-income countries should receive magnesium sulfate due to favorable cost-benefit ratio. 1 In high-income settings with higher administration costs, selective use is reasonable for: 1

• Women with preeclampsia who have proteinuria and severe hypertension (≥150/100 mm Hg with 2+ proteinuria or ≥160/110 mm Hg with 3+ proteinuria) 1
• Women with at least 2 signs or symptoms of imminent eclampsia (headache, visual symptoms, or clonus) 1
• All women with preeclampsia with severe features should receive magnesium sulfate for seizure prophylaxis 1, 7

Standard Dosing Regimen

The dosing regimens from the Eclampsia and MAGPIE trials should be used: 1

• Initial dose: 10-14 g total 2
  • IV: 4-5 g in 250 mL of 5% dextrose or 0.9% saline infused over 15-20 minutes 2
  • Simultaneously, IM: 10 g (5 g in each buttock) 2
• Maintenance: 4-5 g IM into alternate buttocks every 4 hours as needed 2
• Alternative maintenance: 1-2 g/hour by constant IV infusion 2
• Maximum daily dose: 30-40 g per 24 hours 2

Duration of Therapy

• Continue magnesium sulfate for 24 hours postpartum 1
• One Latin American study found no additional benefit of continuing beyond 8 g pre-delivery for 24 hours postpartum, but this requires confirmation in other populations 1
• Eclampsia can occur postpartum, justifying continued prophylaxis 1

Important Safety Considerations

Monitoring Requirements

Each unit must have a consistent policy incorporating appropriate monitoring and recognition of magnesium sulfate infusion risks: 1

• Check patellar reflexes before each IM dose 2
• Ensure adequate respiratory function (rate >16/min) 2
• Monitor serum magnesium levels, targeting 6 mg/100 mL for seizure control 2
• Deep tendon reflexes disappear at plasma levels approaching 10 mEq/L 2
• Respiratory paralysis may occur at 10 mEq/L 2
• Heart block can occur at 10 mEq/L or lower 2
• Serum concentrations >12 mEq/L may be fatal 2

Contraindications and Precautions

• In severe renal insufficiency, maximum dose is 20 g/48 hours with frequent serum magnesium monitoring 2
• Continuous use beyond 5-7 days in pregnancy can cause fetal abnormalities 2
• Magnesium is excreted solely by the kidneys at a rate proportional to plasma concentration and glomerular filtration 2
• Calcium IV administration can antagonize central and peripheral effects of magnesium toxicity 2

Drug Interactions

• Myocardial depression may occur when combining calcium channel blockers with IV magnesium 8
• Magnesium may reduce antibiotic activity of streptomycin, tetracycline, and tobramycin when given together 2

Additional Benefits

Beyond maternal seizure prevention, magnesium sulfate provides:

• Fetal neuroprotection for extremely preterm neonates 9, 10
• Potential benefits in anesthesia management 9
• Improved management of preeclampsia with fetal growth restriction through enhanced uteroplacental perfusion 6